siNAs Targeting DBH for Glaucoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, particularly primary open-angle glaucoma, often focus on lowering intraocular pressure but may not address the root cause of excessive noradrenergic activation, which contributes to optic neuropathy and visual field loss.
Innovation Solution
The use of short interfering nucleic acids (siNAs) to mediate gene silencing of dopamine-beta-hydroxylase (DBH), the final enzyme in noradrenaline synthesis, to reduce excessive noradrenergic activation and thereby treat or prevent ophthalmic diseases associated with elevated intraocular pressure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stress or pressure
If traditional glaucoma treatments (beta-blockers, alpha2 agonists) are used to lower intraocular pressure, then intraocular pressure is reduced, but the root cause of excessive noradrenergic activation is not addressed
Solution Approach 1:
The invention extracts and targets the root cause of the disease by using siRNA to specifically silence the DBH gene, which is responsible for noradrenaline synthesis. This approach removes the underlying pathological mechanism (excessive noradrenergic activation) rather than merely managing the symptom (elevated IOP), thereby addressing both the immediate pressure issue and the root cause simultaneously
Solution Approach 2:
The siRNA molecules are designed to preemptively block the synthesis of noradrenaline by targeting DBH enzyme production before excessive noradrenergic activation can occur. By preventing the formation of the problematic neurotransmitter at its source, the treatment proactively addresses the disease mechanism before it can fully manifest and cause damage
2Reliability
If noradrenaline synthesis is reduced through gene silencing, then excessive noradrenergic activation is decreased, but the complexity of the treatment approach increases
Solution Approach 1:
The invention uses siRNA molecules as intermediary agents that mediate between the therapeutic goal (reducing noradrenergic activation) and the target (DBH gene). These small interfering RNA molecules serve as the connecting mechanism that delivers the therapeutic effect through a well-established biological pathway (RNA interference), thereby simplifying the overall treatment approach while maintaining high effectiveness
Solution Approach 2:
The siRNA molecules utilize the cell's own RNA interference machinery to achieve gene silencing. By harnessing the natural cellular processes for degrading target mRNA and suppressing protein synthesis, the treatment leverages the body's inherent mechanisms rather than requiring external complex systems, thereby reducing treatment complexity while maintaining therapeutic reliability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a localized and sustained therapeutic effect by downregulating dopamine-beta-hydroxylase expression, potentially reducing intraocular pressure and slowing optic neuropathy progression, offering an alternative to traditional glaucoma treatments.
Implementation Method 1
The use of short interfering nucleic acids (siNAs) to mediate gene silencing of dopamine-beta-hydroxylase (DBH), the final enzyme in noradrenaline synthesis
Data Source
AI summary
The present disclosure relates to method of producing and using short interfering nucleic acids (siNAs) for preventing or reversing progressive optical neuropathy associated with the elevation of intraocular pressure due to excessive noradrenergic activation. In particular, this disclosure relates to the method of producing and using siNAs for or reversing progressive optical neuropathy, wherein the optical neuropathy is selected from the following list: diabetic retinopathy, infections, inflammation, uveitis and glaucoma, such as open-angle glaucoma, close-angle glaucoma, normal pressure glaucoma, congenital glaucoma, secondary glaucoma, pigmentary glaucoma, pseudoexfoliative glaucoma, traumatic glaucoma, neovascular glaucoma, endothelial iridocorneal syndrome and uveitic glaucoma. The present disclosure is also directed to interfering RNA duplexes and vectors encoding such interfering RNA duplexes.